Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements - Additional Information (Details)

v3.20.2
Sponsored Research and Clinical Trial Agreements - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 01, 2020
Jun. 30, 2020
May 31, 2020
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Research and Development Expense (Excluding Acquired in Process Cost)       $ 13,298 $ 14,571 $ 43,868 $ 56,355  
Oncogenuity [Member]                
Cost of the SRA       200   300   $ 0
Funding commitment period     5 years          
Mustang Bio, Inc [Member]                
Payments For Research And Development Expenses       800        
Maximum cost associated with COH   $ 2,400            
Cellvation [Member]                
Cost of the SRA       0 $ 100 0 $ 100  
Maximum [Member] | Oncogenuity [Member]                
Sponsor Research Agreement Funding Commitment     $ 4,800          
Mustang Bio, Inc [Member]                
Cost of the SRA       $ 100   $ 800    
St. Jude - XSCID (MB-107) [Member] | Mustang [Member]                
Payment of Upfront Fees $ 1,100